🇺🇸 CC-220 in United States

11 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 23 April 2025 – 23 April 2026
• Total reports: 11

Most-reported reactions

1. Sepsis — 2 reports (18.18%)
2. Breast Cancer Recurrent — 1 report (9.09%)
3. Corneal Epithelium Defect — 1 report (9.09%)
4. False Positive Investigation Result — 1 report (9.09%)
5. Human Chorionic Gonadotropin Increased — 1 report (9.09%)
6. Malignant Melanoma — 1 report (9.09%)
7. Plasmacytoma — 1 report (9.09%)
8. Pneumonia — 1 report (9.09%)
9. Squamous Cell Carcinoma Of Skin — 1 report (9.09%)
10. Therapeutic Product Effect Decreased — 1 report (9.09%)

Source database →

Frequently asked questions

Is CC-220 approved in United States?

CC-220 does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for CC-220 in United States?

Celgene is the originator. The local marketing authorisation holder may differ — check the official source linked above.